<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36920699</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>1407</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>Pseudotyped Viruses for Enterovirus.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>228</EndPage><MedlinePgn>209-228</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-981-99-0113-5_11</ELocationID><Abstract><AbstractText>Using a non-pathogenic pseudotyped virus as a surrogate for a wide-type virus in scientific research complies with the recent requirements for biosafety. Enterovirus (EV) contains many species of viruses, which are a type of nonenveloped virus. The preparation of its corresponding pseudotyped virus often needs customized construction compared to some enveloped viruses. This article describes the procedures and challenges in the construction of pseudotyped virus for enterovirus (pseudotyped enterovirus, EVpv) and also introduces the application of EVpv in basic virological research, serological monitoring, and the detection of neutralizing antibody (NtAb).</AbstractText><CopyrightInformation>© 2023. The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus &amp; Enterovirus Vaccines, Institute for Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Lisha</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Minhai biotechnology Co. Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus &amp; Enterovirus Vaccines, Institute for Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus &amp; Enterovirus Vaccines, Institute for Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus &amp; Enterovirus Vaccines, Institute for Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000089942" MajorTopicYN="N">Viral Pseudotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Neutralizing antibody</Keyword><Keyword MajorTopicYN="N">Pseudotyped virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>12</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36920699</ArticleId><ArticleId IdType="doi">10.1007/978-981-99-0113-5_11</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nikonov, O.S., Chernykh, E.S., Garber, M.B., Nikonova, E.Y.: Enteroviruses: classification, diseases they cause, and approaches to development of antiviral drugs. Biochem. 82, 1615–1631 (2017). https://doi.org/10.1134/s0006297917130041</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/s0006297917130041</ArticleId></ArticleIdList></Reference><Reference><Citation>Royston, L., Tapparel, C.: Rhinoviruses and respiratory enteroviruses: not as simple as ABC. Viruses. 8 (2016). https://doi.org/10.3390/v8010016</Citation></Reference><Reference><Citation>Jubelt, B., Lipton, H.L.: Enterovirus/picornavirus infections. Handb. Clin. Neurol. 123, 379–416 (2014). https://doi.org/10.1016/b978-0-444-53488-0.00018-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-444-53488-0.00018-3</ArticleId><ArticleId IdType="pubmed">25015496</ArticleId></ArticleIdList></Reference><Reference><Citation>Suresh, S., Forgie, S., Robinson, J.: Non-polio enterovirus detection with acute flaccid paralysis: a systematic review. J. Med. Virol. 90, 3–7 (2018). https://doi.org/10.1002/jmv.24933</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24933</ArticleId><ArticleId IdType="pubmed">28857219</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort, M., Grassly, N.C.: Serotype-specific immunity explains the incidence of diseases caused by human enteroviruses. Science. 361, 800–803 (2018). https://doi.org/10.1126/science.aat6777</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat6777</ArticleId><ArticleId IdType="pubmed">30139872</ArticleId><ArticleId IdType="pmc">6559928</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste, M.S.: Progress of polio eradication and containment requirements after eradication. Transfusion. 58(Suppl 3), 3078–3083 (2018). https://doi.org/10.1111/trf.15018</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15018</ArticleId><ArticleId IdType="pubmed">30536438</ArticleId><ArticleId IdType="pmc">8963859</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer, R., Lina, B., Shetty, J.: Acute flaccid myelitis caused by enterovirus D68: case definitions for use in clinical practice. Eur. J. Paediatr. Neurol. 23, 235–239 (2019). https://doi.org/10.1016/j.ejpn.2019.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpn.2019.01.001</ArticleId><ArticleId IdType="pubmed">30670331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers, T., et al.: Acute flaccid myelitis in the United States: 2015–2017. Pediatrics. 144 (2019). https://doi.org/10.1542/peds.2019-1619</Citation></Reference><Reference><Citation>Cui, A., et al.: An outbreak of aseptic meningitis caused by coxsackievirus A9 in Gansu, the People’s Republic of China. Virol. J. 7, 72 (2010). https://doi.org/10.1186/1743-422x-7-72</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422x-7-72</ArticleId><ArticleId IdType="pubmed">20367886</ArticleId><ArticleId IdType="pmc">2907575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, H.J., et al.: A different epidemiology of Enterovirus A and Enterovirus B co-circulating in Korea, 2012–2019. J. Pediatric Infect. Dis. Soc. 10, 398–407 (2021). https://doi.org/10.1093/jpids/piaa111</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piaa111</ArticleId><ArticleId IdType="pubmed">33150450</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito, S., Bosis, S., Niesters, H., Principi, N.: Enterovirus D68 infection. Viruses. 7, 6043–6050 (2015). https://doi.org/10.3390/v7112925</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7112925</ArticleId><ArticleId IdType="pubmed">26610548</ArticleId><ArticleId IdType="pmc">4664996</ArticleId></ArticleIdList></Reference><Reference><Citation>Brotons, P., et al.: The positive rhinovirus/enterovirus detection and SARS-CoV-2 persistence beyond the acute infection phase: an intra-household surveillance study. Viruses. 13 (2021). https://doi.org/10.3390/v13081598</Citation></Reference><Reference><Citation>Novikov Iu, I., Stulova, M.A., Lavrova, I.K.: Myocarditis caused by Coxsackie B viruses in adults. Ter. Arkh. 56, 37–43 (1984)</Citation><ArticleIdList><ArticleId IdType="pubmed">6098043</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, W.S., et al.: Acute viral myopericarditis presenting as a transient effusive-constrictive pericarditis caused by coinfection with coxsackieviruses A4 and B3. Korean J. Intern. Med. 27, 216–220 (2012). https://doi.org/10.3904/kjim.2012.27.2.216</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2012.27.2.216</ArticleId><ArticleId IdType="pubmed">22707895</ArticleId><ArticleId IdType="pmc">3372807</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanmugam, J., Raveendranath, M., Balakrishnan, K.G.: Isolation of ECHO virus type-22 from a child with acute myopericarditis—a case report. Indian Heart J. 38, 79–80 (1986)</Citation><ArticleIdList><ArticleId IdType="pubmed">3744414</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara, T., et al.: Myopericarditis associated with ECHO virus type 3 infection—a case report. Jpn. Circ. J. 47, 1274–1280 (1983). https://doi.org/10.1253/jcj.47.1274</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/jcj.47.1274</ArticleId><ArticleId IdType="pubmed">6645036</ArticleId></ArticleIdList></Reference><Reference><Citation>Leendertse, M., et al.: Pleurodynia caused by an echovirus 1 brought back from the tropics. J. Clin. Virol. 58, 490–493 (2013). https://doi.org/10.1016/j.jcv.2013.06.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2013.06.039</ArticleId><ArticleId IdType="pubmed">23938303</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Calvo, T.: Enterovirus infection and type 1 diabetes: unraveling the crime scene. Clin. Exp. Immunol. 195, 15–24 (2019). https://doi.org/10.1111/cei.13223</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13223</ArticleId><ArticleId IdType="pubmed">30307605</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, H., et al.: Characterization of Coxsackievirus A6 strains isolated from children with hand, foot, and mouth disease. Front. Cell. Infect. Microbiol. 11, 700191 (2021). https://doi.org/10.3389/fcimb.2021.700191</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.700191</ArticleId><ArticleId IdType="pubmed">34490141</ArticleId><ArticleId IdType="pmc">8418080</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand, A., et al.: A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021. Euro Surveill. 26 (2021). https://doi.org/10.2807/1560-7917.Es.2021.26.43.2100978</Citation></Reference><Reference><Citation>Wright, P.W., Strauss, G.H., Langford, M.P.: Acute hemorrhagic conjunctivitis. Am. Fam. Physician. 45, 173–178 (1992)</Citation><ArticleIdList><ArticleId IdType="pubmed">1309404</ArticleId></ArticleIdList></Reference><Reference><Citation>Langford, M.P., Anders, E.A., Burch, M.A.: Acute hemorrhagic conjunctivitis: anti-coxsackievirus A24 variant secretory immunoglobulin A in acute and convalescent tear. Clin. Ophthalmol. 9, 1665–1673 (2015). https://doi.org/10.2147/opth.S85358</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/opth.S85358</ArticleId><ArticleId IdType="pubmed">26392747</ArticleId><ArticleId IdType="pmc">4574852</ArticleId></ArticleIdList></Reference><Reference><Citation>ICTV Picornaviridae, Genus Enterovirus. https://talk.ictvonline.org/ictv-reports/ictv_online_report/positive-sense-rna-viruses/w/picornaviridae/681/genus-enterovirus . (2022)</Citation></Reference><Reference><Citation>Zell, R., et al.: ICTV virus taxonomy profile: picornaviridae. J. Gen. Virol. 98, 2421–2422 (2017). https://doi.org/10.1099/jgv.0.000911</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000911</ArticleId><ArticleId IdType="pubmed">28884666</ArticleId><ArticleId IdType="pmc">5725991</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste, M.S., Maher, K., Kilpatrick, D.R., Pallansch, M.A.: Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J. Virol. 73, 1941–1948 (1999). https://doi.org/10.1128/jvi.73.3.1941-1948.1999</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.73.3.1941-1948.1999</ArticleId><ArticleId IdType="pubmed">9971773</ArticleId><ArticleId IdType="pmc">104435</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmenberg, A.C., et al.: Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science. 324, 55–59 (2009). https://doi.org/10.1126/science.1165557</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165557</ArticleId><ArticleId IdType="pubmed">19213880</ArticleId><ArticleId IdType="pmc">3923423</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmonds, P., et al.: Proposals for the classification of human rhinovirus species C into genotypically assigned types. J. Gen. Virol. 91, 2409–2419 (2010). https://doi.org/10.1099/vir.0.023994-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.023994-0</ArticleId><ArticleId IdType="pubmed">20610666</ArticleId></ArticleIdList></Reference><Reference><Citation>Belsham, G.J., Jackson, R.J.: Translation initiation on picornavirus RNA. In: Translational control of gene expression, pp. 869–900. Cold Spring Harbor (2000)</Citation></Reference><Reference><Citation>Toyoda, H., et al.: A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell. 45, 761–770 (1986). https://doi.org/10.1016/0092-8674(86)90790-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(86)90790-7</ArticleId><ArticleId IdType="pubmed">3011278</ArticleId></ArticleIdList></Reference><Reference><Citation>Mousnier, A., et al.: Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus. Nat. Chem. 10, 599–606 (2018). https://doi.org/10.1038/s41557-018-0039-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41557-018-0039-2</ArticleId><ArticleId IdType="pubmed">29760414</ArticleId><ArticleId IdType="pmc">6015761</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen, J., Thibaut, H.J., Strating, J., van Kuppeveld, F.J.M.: The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 16, 368–381 (2018). https://doi.org/10.1038/s41579-018-0005-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, Z., et al.: A simple and safe antibody neutralization assay based on polio pseudoviruses. Hum. Vaccin. Immunother. 15, 349–357 (2019). https://doi.org/10.1080/21645515.2018.1526553</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1526553</ArticleId><ArticleId IdType="pubmed">30273512</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, J., et al.: Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum. J. Virol. Methods. 187, 362–367 (2013). https://doi.org/10.1016/j.jviromet.2012.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.11.014</ArticleId><ArticleId IdType="pubmed">23178532</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, P., et al.: Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J. Biol. Chem. 287, 6406–6420 (2012). https://doi.org/10.1074/jbc.M111.301622</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.301622</ArticleId><ArticleId IdType="pubmed">22219187</ArticleId><ArticleId IdType="pmc">3307280</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, H., et al.: Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV-A71 pseudovirus-based assay. PLoS One. 9, e100545 (2014). https://doi.org/10.1371/journal.pone.0100545</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100545</ArticleId><ArticleId IdType="pubmed">24964084</ArticleId><ArticleId IdType="pmc">4070950</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao, X.T., et al.: Establishment and preliminary application of a pseudovirus luciferase assay for quantitative detection of coxsackievirus A16 neutralizing antibody. Chin. J. Viral Dis. 6, 6–11 (2016). https://doi.org/10.16505/j.2095-0136.2016.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.16505/j.2095-0136.2016.01.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, Y., et al.: A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies. Hum. Vaccin. Immunother. 14, 3034–3040 (2018). https://doi.org/10.1080/21645515.2018.1504540</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1504540</ArticleId><ArticleId IdType="pubmed">30060712</ArticleId><ArticleId IdType="pmc">6343605</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, P., et al.: A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3. J. Virol. Methods. 232, 1–7 (2016). https://doi.org/10.1016/j.jviromet.2016.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2016.02.010</ArticleId><ArticleId IdType="pubmed">26947399</ArticleId><ArticleId IdType="pmc">7113863</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, P., et al.: Development of a pseudovirus based assay for measuring neutralizing antibodies against coxsackievirus B5. J. Virol. Methods. 246, 21–26 (2017). https://doi.org/10.1016/j.jviromet.2017.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2017.04.005</ArticleId><ArticleId IdType="pubmed">28435072</ArticleId><ArticleId IdType="pmc">7113871</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, S., et al.: Comparison of the neutralizing activities of antibodies in clinical sera against both Sabin and wild-type polio pseudoviruses. J. Virol. Methods. 300, 114376 (2022). https://doi.org/10.1016/j.jviromet.2021.114376</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114376</ArticleId><ArticleId IdType="pubmed">34826519</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, K., et al.: Development of a pseudovirus-based assay for measuring neutralizing antibodies against Coxsackievirus A10. Hum. Vaccin. Immunother. 16, 1434–1440 (2020). https://doi.org/10.1080/21645515.2019.1691404</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2019.1691404</ArticleId><ArticleId IdType="pubmed">31851566</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong, F.Y., et al.: Construction of enterovirus D68 pseudovirus. Prog. Microbiol. Immunol. 47, 8–14 (2019). https://doi.org/10.13309/j.cnki.pmi.2019.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.13309/j.cnki.pmi.2019.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kräusslich, H.G., Wimmer, E.: Viral proteinases. Annu. Rev. Biochem. 57, 701–754 (1988). https://doi.org/10.1146/annurev.bi.57.070188.003413</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.bi.57.070188.003413</ArticleId><ArticleId IdType="pubmed">3052288</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallansch, M.A., et al.: Protein processing map of poliovirus. J. Virol. 49, 873–880 (1984). https://doi.org/10.1128/jvi.49.3.873-880.1984</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.49.3.873-880.1984</ArticleId><ArticleId IdType="pubmed">6321771</ArticleId><ArticleId IdType="pmc">255549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ypma-Wong, M.F., Filman, D.J., Hogle, J.M., Semler, B.L.: Structural domains of the poliovirus polyprotein are major determinants for proteolytic cleavage at Gln-Gly pairs. J. Biol. Chem. 263, 17846–17856 (1988)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)77912-5</ArticleId><ArticleId IdType="pubmed">2846581</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommergruber, W., et al.: Cleavage specificity on synthetic peptide substrates of human rhinovirus 2 proteinase 2A. J. Biol. Chem. 267, 22639–22644 (1992)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)41720-6</ArticleId><ArticleId IdType="pubmed">1331062</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallai, P.V., et al.: Cleavage of synthetic peptides by purified poliovirus 3C proteinase. J. Biol. Chem. 264, 9738–9741 (1989)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)81718-5</ArticleId><ArticleId IdType="pubmed">2542331</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kuppeveld, F.J., Galama, J.M., Zoll, J., Melchers, W.J.: Genetic analysis of a hydrophobic domain of coxsackie B3 virus protein 2B: a moderate degree of hydrophobicity is required for a cis-acting function in viral RNA synthesis. J. Virol. 69, 7782–7790 (1995). https://doi.org/10.1128/jvi.69.12.7782-7790.1995</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.69.12.7782-7790.1995</ArticleId><ArticleId IdType="pubmed">7494289</ArticleId><ArticleId IdType="pmc">189721</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kuppeveld, F.J., Galama, J.M., Zoll, J., van den Hurk, P.J., Melchers, W.J.: Coxsackie B3 virus protein 2B contains cationic amphipathic helix that is required for viral RNA replication. J. Virol. 70, 3876–3886 (1996). https://doi.org/10.1128/jvi.70.6.3876-3886.1996</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.70.6.3876-3886.1996</ArticleId><ArticleId IdType="pubmed">8648724</ArticleId><ArticleId IdType="pmc">190265</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue, R.C., Pfaller, C.K., Cattaneo, R.: Cyclical adaptation of measles virus quasispecies to epithelial and lymphocytic cells: to V, or not to V. PLoS Pathog. 15, e1007605 (2019). https://doi.org/10.1371/journal.ppat.1007605</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007605</ArticleId><ArticleId IdType="pubmed">30768648</ArticleId><ArticleId IdType="pmc">6395005</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland, J.J.: Transitions in understanding of RNA viruses: a historical perspective. Curr. Top. Microbiol. Immunol. 299, 371–401 (2006). https://doi.org/10.1007/3-540-26397-7_14</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/3-540-26397-7_14</ArticleId><ArticleId IdType="pubmed">16568907</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo, E., Sheldon, J., Perales, C.: Viral quasispecies evolution. Microbiol Mol Biol Rev. 76, 159–216 (2012). https://doi.org/10.1128/mmbr.05023-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mmbr.05023-11</ArticleId><ArticleId IdType="pubmed">22688811</ArticleId><ArticleId IdType="pmc">3372249</ArticleId></ArticleIdList></Reference><Reference><Citation>Sánchez-Campos, S., et al.: Differential Shape of geminivirus mutant spectra across cultivated and wild hosts with invariant viral consensus sequences. Front. Plant Sci. 9, 932 (2018). https://doi.org/10.3389/fpls.2018.00932</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpls.2018.00932</ArticleId><ArticleId IdType="pubmed">30013589</ArticleId><ArticleId IdType="pmc">6036239</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo, E., Perales, C.: Quasispecies and virus. EBJ. 47, 443–457 (2018). https://doi.org/10.1007/s00249-018-1282-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00249-018-1282-6</ArticleId><ArticleId IdType="pubmed">29397419</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao, Y., et al.: RNA recombination enhances adaptability and is required for virus spread and virulence. Cell Host Microbe. 19, 493–503 (2016). https://doi.org/10.1016/j.chom.2016.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.03.009</ArticleId><ArticleId IdType="pubmed">27078068</ArticleId><ArticleId IdType="pmc">4840895</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno, E., et al.: Internal disequilibria and phenotypic diversification during replication of Hepatitis C virus in a noncoevolving cellular environment. J. Virol. 91 (2017). https://doi.org/10.1128/jvi.02505-16</Citation></Reference><Reference><Citation>Diamond, D.C., et al.: Antigenic variation and resistance to neutralization in poliovirus type 1. Science. 229, 1090–1093 (1985). https://doi.org/10.1126/science.2412292</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2412292</ArticleId><ArticleId IdType="pubmed">2412292</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondel, B., et al.: Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J. Virol. 57, 81–90 (1986). https://doi.org/10.1128/jvi.57.1.81-90.1986</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.57.1.81-90.1986</ArticleId><ArticleId IdType="pubmed">2416957</ArticleId><ArticleId IdType="pmc">252701</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo, E., Perales, C.: Viral quasispecies. PLoS Genet. 15, e1008271 (2019). https://doi.org/10.1371/journal.pgen.1008271</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1008271</ArticleId><ArticleId IdType="pubmed">31622336</ArticleId><ArticleId IdType="pmc">6797082</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter, D.C., et al.: Demonstration of the specificity of poliovirus encapsidation using a novel replicon which encodes enzymatically active firefly luciferase. Virology. 243, 1–11 (1998). https://doi.org/10.1006/viro.1998.9046</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1998.9046</ArticleId><ArticleId IdType="pubmed">9527910</ArticleId></ArticleIdList></Reference><Reference><Citation>Blom, N., Hansen, J., Blaas, D., Brunak, S.: Cleavage site analysis in picornaviral polyproteins: discovering cellular targets by neural networks. Protein Sci. 5, 2203–2216 (1996). https://doi.org/10.1002/pro.5560051107</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.5560051107</ArticleId><ArticleId IdType="pubmed">8931139</ArticleId><ArticleId IdType="pmc">2143287</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia, X.Y., Van Eden, M., Busch, M.G., Ehrenfeld, E., Summers, D.F.: Trans-encapsidation of a poliovirus replicon by different picornavirus capsid proteins. J. Virol. 72, 7972–7977 (1998). https://doi.org/10.1128/jvi.72.10.7972-7977.1998</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.72.10.7972-7977.1998</ArticleId><ArticleId IdType="pubmed">9733835</ArticleId><ArticleId IdType="pmc">110132</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, J., et al.: Involvement of VCP/UFD1/Nucleolin in the viral entry of Enterovirus A species. Virus Res. 283, 197974 (2020). https://doi.org/10.1016/j.virusres.2020.197974</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2020.197974</ArticleId><ArticleId IdType="pubmed">32289342</ArticleId><ArticleId IdType="pmc">7151541</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, J., et al.: Myristoylation of EV-A71 VP4 is essential for infectivity and interaction with membrane structure. Virol. Sin. 35, 599–613 (2020). https://doi.org/10.1007/s12250-020-00226-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00226-1</ArticleId><ArticleId IdType="pubmed">32399947</ArticleId><ArticleId IdType="pmc">7736455</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/GAPIII_2014.pdf</Citation></Reference><Reference><Citation>Arita, M., Iwai-Itamochi, M.: Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test. Sci. Rep. 9, 11970 (2019). https://doi.org/10.1038/s41598-019-48534-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48534-1</ArticleId><ArticleId IdType="pubmed">31427704</ArticleId><ArticleId IdType="pmc">6700111</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley, E.B., et al.: Intestinal immune responses to type 2 Oral Polio Vaccine (OPV) challenge in infants previously immunized with Bivalent OPV and either high-dose or standard inactivated polio vaccine. J. Infect. Dis. 217, 371–380 (2018). https://doi.org/10.1093/infdis/jix556</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix556</ArticleId><ArticleId IdType="pubmed">29304199</ArticleId><ArticleId IdType="pmc">5853416</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright, E., et al.: Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses. Virology. 408, 183–189 (2010). https://doi.org/10.1016/j.virol.2010.09.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2010.09.014</ArticleId><ArticleId IdType="pubmed">20951400</ArticleId></ArticleIdList></Reference><Reference><Citation>Molesti, E., et al.: Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies. J Immunol Res. 2014, 457932 (2014). https://doi.org/10.1155/2014/457932</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/457932</ArticleId><ArticleId IdType="pubmed">25101305</ArticleId><ArticleId IdType="pmc">4101955</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, X., et al.: Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71. PLoS One. 8, e64116 (2013). https://doi.org/10.1371/journal.pone.0064116</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064116</ArticleId><ArticleId IdType="pubmed">23755115</ArticleId><ArticleId IdType="pmc">3673970</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyndrickx, L., et al.: International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One. 7, e36438 (2012). https://doi.org/10.1371/journal.pone.0036438</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0036438</ArticleId><ArticleId IdType="pubmed">22590544</ArticleId><ArticleId IdType="pmc">3348930</ArticleId></ArticleIdList></Reference><Reference><Citation>Louder, M.K., et al.: HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology. 339, 226–238 (2005). https://doi.org/10.1016/j.virol.2005.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.06.003</ArticleId><ArticleId IdType="pubmed">16005039</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright, P.F., et al.: Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J. Infect. Dis. 209, 1628–1634 (2014). https://doi.org/10.1093/infdis/jit671</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit671</ArticleId><ArticleId IdType="pubmed">24459191</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright, P.F., et al.: Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect. Dis. 16, 1377–1384 (2016). https://doi.org/10.1016/s1473-3099(16)30169-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(16)30169-4</ArticleId><ArticleId IdType="pubmed">27638357</ArticleId><ArticleId IdType="pmc">5611465</ArticleId></ArticleIdList></Reference><Reference><Citation>Arya, S.C., Agarwal, N.: Poliovirus neutralization test with poliovirus pseudovirus to measure neutralizing antibody in humans. CVI. 19, 458; author reply 459 (2012). https://doi.org/10.1128/cvi.05568-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cvi.05568-11</ArticleId><ArticleId IdType="pubmed">22371252</ArticleId><ArticleId IdType="pmc">3294615</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, S., et al.: A safe and sensitive enterovirus A71 infection model based on human SCARB2 knock-in mice. Vaccine. 34, 2729–2736 (2016). https://doi.org/10.1016/j.vaccine.2016.04.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.04.029</ArticleId><ArticleId IdType="pubmed">27102822</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, X., et al.: Establishment of bioluminescent imaging mouse model for coxsackievirus A6 vaccine using the pseudovirus system. Chin. J. Viral Dis. 8, 515–520 (2018). https://doi.org/10.16505/j.2095-0136.2018.0108</Citation><ArticleIdList><ArticleId IdType="doi">10.16505/j.2095-0136.2018.0108</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, L., et al.: Identification of luteolin as enterovirus 71 and coxsackievirus A16 inhibitors through reporter viruses and cell viability-based screening. Viruses. 6, 2778–2795 (2014). https://doi.org/10.3390/v6072778</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v6072778</ArticleId><ArticleId IdType="pubmed">25036464</ArticleId><ArticleId IdType="pmc">4113793</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>